Newswise Feature Channel: Clinical Trials

OcuDyne Announces Positive Results for the OPTiC System(tm) 6-Month Clinical Trial in the Treatment of Geographic Atrophy

Ocudyne, Inc. — Mon, 09 Sep 2024 15:05:21 EST

A medical device company utilizing a novel approach to treat ocular disease, announced today the successful completion of a pilot study using its proprietary OPTiC System for treating Age-Related Macular Degeneration (AMD).

MD Anderson Research Highlights Special Edition: 2024 World Conference on Lung Cancer

University of Texas MD Anderson Cancer Center — Mon, 09 Sep 2024 14:05:55 EST

The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features compelling data on lung cancer advances presented by MD Anderson researchers at the 2024 World Conference on Lung Cancer.

Hackensack Meridian Mountainside Medical Center Chosen as One of Six Global Sites for Innovative MICRO 2.0 Clinical Trial

Hackensack Meridian Health (Mountainside Medical Center) — Mon, 09 Sep 2024 14:05:11 EST

Mountainside is a site for the Genetesis MICRO 2.0 Clinical Trial, advancing non-invasive cardiac diagnostics to evaluate coronary microvascular dysfunction. This study explores how magnetocardiography could revolutionize heart condition diagnosis and management.

UC Irvine Receives Record $668 Million in Research Funding for Fiscal 2023-24

University of California, Irvine — Mon, 09 Sep 2024 13:05:04 EST

University of California, Irvine scholars, scientists and physicians continue to blaze new paths to help improve the world. In fiscal 2023-24, which ended June 30, UC Irvine received the most research funding in campus history: $668 million in grants and contracts.

How the Scars of Demolished Brain Tumors Seed Relapse

Ludwig Cancer Research — Mon, 09 Sep 2024 12:05:48 EST

A Ludwig Cancer Research study has discovered that recurrent tumors of the aggressive brain cancer glioblastoma multiforme (GBM) grow out of the fibrous scars of malignant predecessors destroyed by interventions such as radiotherapy, surgery and immunotherapy.

Study suggests US droughts, rainy extremes becoming more severe

Ohio State University — Fri, 06 Sep 2024 09:05:56 EST

Severe drought in the American Southwest and Mexico and more severe wet years in the Northeast are the modern norm in North America, according to new research - and the analysis suggests these seasonal patterns will be more extreme in the future.

Bone Marrow Transplant Donor and Recipient to Meet at Survivor Picnic

Loyola Medicine — Thu, 05 Sep 2024 14:05:06 EST

On Sunday, September 8, a 27-year-old Loyola Medicine patient will meet for the first time the Arizona man who donated bone marrow on three separate occasions to help save her life.

Tempo Therapeutics Announces First Patient Dosed in Clinical Trial of TT101 for Tissue Repair in Skin Cancer Surgery

Tempo Therapeutics, Inc — Thu, 05 Sep 2024 11:05:47 EST

Tempo Therapeutics, Inc. ("Tempo"), a leader in tissue engineering and regenerative medicine, has announced the dosing of the first patients in the MOSAIC Trial, a clinical trial for TT101, the company's lead candidate for tissue regeneration using its proprietary MAP technology.

Adding anti-clotting drugs to stroke care ineffective, clinical trial finds

Washington University in St. Louis — Wed, 04 Sep 2024 17:00:00 EST

Opeolu Adeoye, MD a professor of emergency medicine at Washington University School of Medicine in St. Louis, led a national clinical trial that found that two anti-coagulant medications are ineffective at improving post-treatment outcomes for stroke patients.

Chris Evert's Ovarian Cancer Diagnosis Highlights the Importance of Yearly Gynecologic Appointments

Hackensack Meridian Health — Wed, 04 Sep 2024 15:05:41 EST

Breaking the link between obesity and atrial fibrillation with a new cellular target

University of Illinois Chicago — Wed, 04 Sep 2024 08:55:04 EST

Blocking oxidative stress enzyme prevents, even reverses, heart condition in lab models

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, joins Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School, and Robert Wood Johnson University Hospital as Chief of Neurosurgical Oncology

Rutgers Cancer Institute — Wed, 04 Sep 2024 07:00:00 EST

Rutgers Cancer Institute, the state's only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health, have appointed Jonathan H. Sherman, MD, FAANS, FCNS, FACS as chief of Neurosurgical Oncology at Rutgers Cancer Institute.

Amos Joins UNM Cancer Center

University of New Mexico Comprehensive Cancer Center — Tue, 03 Sep 2024 12:05:54 EST

Christopher Amos, PhD, will join The University of New Mexico Comprehensive Cancer Center on October 1, Yolanda Sanchez, PhD, announced. Sanchez leads the UNM Comprehensive Cancer Center as Director and CEO. Amos will serve as Associate Director for Population Sciences and Cancer Control at the UNM Cancer Center and will also serve as Director of the UNM Health Sciences Center (HSC) Data Science Initiative.

Penn study finds taking semaglutide for weight management does not increase risk of depression or suicidal behavior in people without known major psychopathology

Perelman School of Medicine at the University of Pennsylvania — Tue, 03 Sep 2024 11:00:00 EST

Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA Internal Medicine. Both the Food and Drug Administration (FDA) and the European Medicines Agency are actively monitoring the psychiatric safety of semaglutide and similar medications after post marketing surveillance reports of depression, suicidal thoughts (ideation), and suicidal behavior in patients taking the drugs for the management of type 2 diabetes or obesity.

SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack

Mount Sinai Health System — Sun, 01 Sep 2024 04:05:02 EST

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.

CRF Announces TCT 2024 Late-Breaking Clinical Trials and Science

Cardiovascular Research Foundation (CRF) — Tue, 27 Aug 2024 16:05:16 EST

The Cardiovascular Research Foundation (CRF) is pleased to announce the late-breaking clinical trials and science to be featured at TCT 2024.

Internationally recognized cancer expert joins UCI Health as cancer center deputy director

University of California, Irvine — Mon, 26 Aug 2024 14:05:45 EST

Internationally recognized cancer expert Dr. Miguel A. Villalona-Calero has joined the UCI Health Chao Family Comprehensive Cancer Center as its deputy director and chief of the Division of Hematology-Oncology at the UC Irvine School of Medicine.

Mesenchymal stem cells: A promising therapeutic avenue for non-alcoholic fatty liver disease

World Journal of Stem Cells — Mon, 26 Aug 2024 12:00:46 EST

Non-alcoholic fatty liver disease (NAFLD) is a pressing global health concern that is associated with metabolic syndrome and obesity. On the basis of the insights provided by Jiang et al, this editorial presents an exploration of the potent

UNM Cancer Center Opens Ovarian Cancer Clinical Trial Using HIPEC Surgery

University of New Mexico Comprehensive Cancer Center — Mon, 26 Aug 2024 11:15:50 EST

The University of New Mexico Comprehensive Cancer Center has opened a clinical trial that applies hyperthermic intraperitoneal chemotherapy (HIPEC) -- a proven surgical technique that is used in digestive system cancers -- to ovarian cancer.

UNM Cancer Center Opens Ovarian Cancer Clinical Trial Using HIPEC Surgery

University of New Mexico Comprehensive Cancer Center — Mon, 26 Aug 2024 08:00:00 EST